Teva plans to take over major chunk of migraine market
![Teva CEO Kåre Schultz | Photo: Amir Cohen/REUTERS / X02077](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12754695.ece/ALTERNATES/schema-16_9/doc7egqf2yn8g71b9mza1ys.jpg)
In future years, more US patients will start treatment with Teva's migraine drug Ajovy.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.